Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07018479 · ClinicalTrials.gov registry record · NA

Effects of a Female Hormone Balance Supplement on Premenstrual Syndrome Symptoms

A NA study of Premenstrual Syndrome, sponsored by Vinabas Formulations SL.

Completed
Registry status
NA
Development phase
38
Enrollment target
1
Study location

NCT07018479 is a NA study of Premenstrual Syndrome that has completed, run by Vinabas Formulations SL. The registered enrollment target is 38 participants, below the 129-participant average among 6 other Premenstrual Syndrome trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07018479, a NA study of Premenstrual Syndrome, has completed, sponsored by Vinabas Formulations SL.

COMPLETED
Registry status
NA
Development phase
38 participants
Enrollment target
1
Study location

Study Summary

This virtual single-group study evaluates the effects of the FemmeBalance supplement on symptoms of premenstrual syndrome (PMS) over four menstrual cycles. The study involves daily intake of the supplement, regular questionnaires, and skin photo submissions for dermatological grading.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT FemmeBalance Supplement Group

Study Locations (1)

Nevada

  • Citruslabs - Las Vegas

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2024-07-30
Est. Completion 2025-01-20
Phase NA

Sponsor

Vinabas Formulations SL

1 total trials

What the Registry Record Tells You About NCT07018479

The ClinicalTrials.gov registry entry for NCT07018479 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 129-participant average among 6 other Premenstrual Syndrome trials with a reported enrollment target (71% lower). The listed sponsor is Vinabas Formulations SL, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Premenstrual Syndrome appearing as the primary indexed condition, and to 1 intervention - of which FemmeBalance Supplement Group is the first listed.

NCT07018479 reports 1 study location spanning 1 distinct geographic area - top geographies include Nevada.

Frequently Asked Questions

What is clinical trial NCT07018479 about?

NCT07018479 is a clinical study titled "Effects of a Female Hormone Balance Supplement on Premenstrual Syndrome Symptoms". This virtual single-group study evaluates the effects of the FemmeBalance supplement on symptoms of premenstrual syndrome (PMS) over four menstrual cycles. The study involves daily intake of the supplement, regular questionnaires, and skin photo submissions for dermatological grading.

What is the current status of trial NCT07018479?

This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2024-07-30. Estimated completion is 2025-01-20.

What conditions does trial NCT07018479 study?

This clinical trial studies the following conditions: Premenstrual Syndrome.

What interventions are being tested in trial NCT07018479?

The interventions under investigation include: FemmeBalance Supplement Group (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT07018479?

This trial is sponsored by Vinabas Formulations SL, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07018479 being conducted?

This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Premenstrual Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.